[go: up one dir, main page]

ZA9811593B - Substantially pure histidine-linked protein polymer conjugates - Google Patents

Substantially pure histidine-linked protein polymer conjugates

Info

Publication number
ZA9811593B
ZA9811593B ZA9811593A ZA9811593A ZA9811593B ZA 9811593 B ZA9811593 B ZA 9811593B ZA 9811593 A ZA9811593 A ZA 9811593A ZA 9811593 A ZA9811593 A ZA 9811593A ZA 9811593 B ZA9811593 B ZA 9811593B
Authority
ZA
South Africa
Prior art keywords
substantially pure
polymer conjugates
linked protein
protein polymer
pure histidine
Prior art date
Application number
ZA9811593A
Other languages
English (en)
Inventor
Seoju Lee
Charles Mcnemar
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Inc filed Critical Enzon Inc
Publication of ZA9811593B publication Critical patent/ZA9811593B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
ZA9811593A 1997-12-19 1998-12-17 Substantially pure histidine-linked protein polymer conjugates ZA9811593B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/994,621 US5985263A (en) 1997-12-19 1997-12-19 Substantially pure histidine-linked protein polymer conjugates

Publications (1)

Publication Number Publication Date
ZA9811593B true ZA9811593B (en) 1999-06-17

Family

ID=25540855

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811593A ZA9811593B (en) 1997-12-19 1998-12-17 Substantially pure histidine-linked protein polymer conjugates

Country Status (14)

Country Link
US (1) US5985263A (xx)
EP (1) EP1039921B1 (xx)
JP (2) JP4157277B2 (xx)
AR (1) AR017888A1 (xx)
AT (1) ATE345142T1 (xx)
AU (1) AU1829099A (xx)
CA (1) CA2312976C (xx)
DE (1) DE69836438T2 (xx)
DK (1) DK1039921T3 (xx)
ES (1) ES2280107T3 (xx)
PE (1) PE20000002A1 (xx)
SG (1) SG165132A1 (xx)
WO (1) WO1999032134A1 (xx)
ZA (1) ZA9811593B (xx)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU762616B2 (en) 1998-10-16 2003-07-03 Biogen Ma Inc. Polymer conjugates of interferon beta-1a and uses
ES2265693T3 (es) 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CA2376057A1 (en) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
JP5095061B2 (ja) * 1999-12-22 2012-12-12 ネクター セラピューティックス ポリ（エチレングリコール）の１−ベンゾトリアゾリル炭酸エステルの調製のための方法
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
KR20030036591A (ko) * 2000-07-12 2003-05-09 그리폰 테라퓨틱스, 인코포레이티드 폴리머-변형 생물활성 합성 키모카인, 및 그것의 제조와사용방법
CN1458846A (zh) * 2000-09-08 2003-11-26 格莱风治疗公司 促红细胞生成性合成蛋白
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
US20020187178A1 (en) * 2001-05-04 2002-12-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids and methods of use thereof
US20030108585A1 (en) * 2001-05-04 2003-06-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
IL159524A0 (en) * 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
MXPA04006855A (es) 2002-01-18 2005-04-19 Biogen Idec Inc Compuestos de polimeros de polialquileno y usos de los mismos.
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1671420A (zh) 2002-06-21 2005-09-21 诺和诺德医疗保健公司 Peg化因子ⅶ糖型
CA2511815A1 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004060299A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US8034900B2 (en) * 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20060134736A1 (en) * 2003-03-28 2006-06-22 Jacobs John W Human growth hormone conjugated with biocompatible polymer
MXPA05010411A (es) * 2003-03-28 2006-05-31 Biopolymed Inc Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen.
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
WO2004089421A2 (en) * 2003-03-31 2004-10-21 Xencor, Inc Methods for rational pegylation of proteins
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
EP1613274B1 (en) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2005016312A1 (en) 2003-08-13 2005-02-24 Nobex Corporation Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
JP2007533298A (ja) 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Ｉｌ−２１の誘導体
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
BRPI0507159A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
JP5460958B2 (ja) * 2004-03-17 2014-04-02 アンチキャンサー インコーポレーテッド タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
KR20070034512A (ko) 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
WO2006014673A2 (en) 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
CA2590429C (en) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions of aminoacyl-trna synthetase and uses thereof
CA2594561C (en) 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
WO2006133088A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
GEP20105124B (en) 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
UA93990C2 (ru) 2005-10-11 2011-03-25 Интермюн, Инк. Соединения и способ ингибирования репликации вируса гепатита c
JP2009520949A (ja) 2005-11-16 2009-05-28 アンブルックス，インコーポレイテッド 非天然アミノ酸を含んでいる組成物および方法
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
BRPI0712008A2 (pt) 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag derivados e análogos de fix prolongados
ES2465473T3 (es) 2006-09-08 2014-06-05 Ambrx, Inc. Transcripción de arnt supresor en células de vertebrado
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
CN105838699A (zh) 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2209494B1 (en) * 2007-10-09 2016-07-20 Polytherics Limited Novel conjugated proteins and peptides
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
KR101656107B1 (ko) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
JP2011519361A (ja) 2008-04-14 2011-07-07 ハロザイム インコーポレイテッド 修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
DK2337846T3 (en) 2008-09-26 2018-03-12 Ambrx Inc NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES
BRPI0919403A2 (pt) 2008-09-26 2017-09-26 Ambrx Inc polipeptídeos modificados de eritropoetina animal e seus usos
ES2724588T3 (es) 2008-12-09 2019-09-12 Halozyme Inc Polipéptidos de PH20 soluble extendida y usos de los mismos
CN102256625B (zh) 2008-12-17 2013-11-20 默沙东公司 单和双peg il10的生产和用途
AU2010225523B2 (en) 2009-03-20 2012-05-24 Hanmi Science Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2459224B1 (en) 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
PE20121707A1 (es) 2009-12-21 2012-12-17 Ambrx Inc Polipeptidos de somatotropina bovina modificados y sus usos
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
KR101963460B1 (ko) 2010-08-17 2019-03-28 암브룩스, 인코포레이티드 변형된 릴랙신 폴리펩타이드 및 그것의 용도
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
AU2012271361B2 (en) 2011-06-17 2017-03-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
MX2014000031A (es) 2011-07-01 2014-07-09 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos.
BR112014002219A2 (pt) 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
EA030440B1 (ru) 2011-10-24 2018-08-31 Галозим, Инк. Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
CN104411324A (zh) 2012-04-04 2015-03-11 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CA2880162C (en) 2012-07-31 2023-04-04 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
ES2728864T3 (es) 2012-08-31 2019-10-29 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
CA2906003C (en) 2013-03-13 2021-07-06 Bioasis Technologies Inc. Fragments of p97 and uses thereof
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
HRP20190881T1 (hr) 2014-08-28 2019-07-12 Halozyme, Inc. Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10370407B2 (en) * 2015-01-21 2019-08-06 The Regents Of The University Of California Affinity-assisted protein modification and recycling
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
HK1245671A1 (zh) 2015-05-29 2018-08-31 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
CN113855804A (zh) 2015-06-15 2021-12-31 小利兰·斯坦福大学托管委员会 用于治疗衰老相关病症的方法和组合物
EP3341012B1 (en) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3373937B1 (en) 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Anti-cd22 antibody-maytansine conjugates and methods of use thereof
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
KR102836360B1 (ko) 2016-04-15 2025-07-23 베크만 컬터, 인코포레이티드 광활성 거대분자 및 그의 용도
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CN110312549B (zh) 2016-12-19 2021-06-29 莫尔豪斯医学院 用于通过抑制外泌体释放来治疗疾病的组合物和方法
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
ES2939112T3 (es) 2017-11-10 2023-04-19 Armo Biosciences Inc Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
WO2019191482A1 (en) 2018-03-30 2019-10-03 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
EP3813867A1 (en) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Treatment of lymmphatic metastases
CN111212661B (zh) 2018-09-11 2023-09-12 北京泰德制药股份有限公司 白介素-2多肽偶联物及其用途
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
PE20211664A1 (es) 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
WO2022266498A1 (en) 2021-06-17 2022-12-22 Nektar Therapeutics Histidine-selective polymer reagents
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
EP4547759A2 (en) 2022-07-01 2025-05-07 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
CN120936679A (zh) 2023-03-17 2025-11-11 贝克曼库尔特有限公司 苯并噻吩并吡咯花菁染料
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
US20250341516A1 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Compositions for use with multiple fluorophores and methods of using

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4810638A (en) * 1986-07-24 1989-03-07 Miles Inc. Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
ATE214940T1 (de) * 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase

Also Published As

Publication number Publication date
WO1999032134A1 (en) 1999-07-01
ATE345142T1 (de) 2006-12-15
ES2280107T3 (es) 2007-09-01
CA2312976C (en) 2012-06-19
DK1039921T3 (da) 2007-04-02
US5985263A (en) 1999-11-16
AU1829099A (en) 1999-07-12
AR017888A1 (es) 2001-10-24
DE69836438D1 (de) 2006-12-28
EP1039921A1 (en) 2000-10-04
JP2001526238A (ja) 2001-12-18
SG165132A1 (en) 2010-10-28
PE20000002A1 (es) 2000-01-18
EP1039921A4 (en) 2004-06-30
DE69836438T2 (de) 2007-09-27
CA2312976A1 (en) 1999-07-01
JP4157277B2 (ja) 2008-10-01
JP2008143897A (ja) 2008-06-26
EP1039921B1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
ZA9811593B (en) Substantially pure histidine-linked protein polymer conjugates
ZA9811590B (en) Interferon polymer conjugates
GB9713980D0 (en) New conjugates
TJ328B (en) Interferron conjugates
PL344341A1 (en) Peptides
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
AU1620099A (en) Ubiquitin-like conjugating protein
GB9700154D0 (en) Peptides
AU1999999A (en) Contryphan peptides
SG77209A1 (en) Polymer
ZA984322B (en) Sucrose-binding proteins
GB9812675D0 (en) Peptides
GB9720784D0 (en) Protein
GB2329182B (en) Polymer blend
GB9716454D0 (en) Polymer
AU1552800A (en) Coupled peptides
GB9807890D0 (en) Peptides
AUPP589498A0 (en) Novel peptides
AUPP298998A0 (en) Novel peptides
AUPP651598A0 (en) Peptides
GB9706119D0 (en) Novel protein
GB9703850D0 (en) Novel protein
GB9714075D0 (en) Novel protein
GB9703827D0 (en) Novel protein